Neoplasie del laringe Diagnosi e trattamento
|
|
- Marion Dorsey
- 6 years ago
- Views:
Transcription
1 Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale d Insegnamento
2 Induction chemotherapy (neo-adjuvant chemotherapy) Any chemotherapy regimen, with proven activity, given BEFORE definitive loco-regional treatment (radiation, surgery or both). Being part of a radical treatment, the final target of induction chemotherapy is: To improve overall survival compared to the current standard treatment(s) OR To achieve the same results of the standard treatment but with lesser toxicity OR To achieve the same results of the standard treatment with the same toxicity but at a lower economical cost
3 Induction chemotherapy Early trials This kind of trials are those considered in the MACH-CN meta-analysis! Second Generation trials
4 Why ICT is so attractive? 1. Good activity 2. Easy to delivery (and physicians are familiar with toxicities!) 3. Marginal but Significant improvement in OS observed in the meta-analysis (only with Cisplatin and 5FU) 4. Perception of a possible conversion from unresectable to resectable tumors or reduced RT volume
5 1 Activity of Induction chemotherapy (ICT) (in randomized trials, ICT arm, P+F only) Author (year) n. of patients subsites O.R.R. after ICT (CR+PR) CT regimen (n. of courses) Domenge C (2000) 157 Oropharynx* Forastiere A** (2003) Lefebvre J-L** (1996) Vermorken*** (2007) Posner (2007) 168 Larynx 97 Hypopharynx larynx 181 All sites 246 All sites 56% ( ) 85% ( ) 86% ( ) 54% ( ) 64% ( ) Cddp + 5FU (x 3) Cddp + 5FU (x 3) Cddp + 5FU (x 3) Cddp + 5FU (x 3) Cddp + 5FU (x 3) * accrual between 1986 and 1992, previous to HPV era ** organ preservation *** unresectable only resectable, unresectable and organ preservation evaluation after the initial two courses
6 2 TOXICITY (CRT) Cumulative analysis (clinical trials only) All pts 394 Cause of death # % Treatment Disease Comorbidities Second primary Unknown Overall % Treatment related death # % All pts 291 Cumulative analysis (clinical practice only) Cause of toxic death 1 # % Bleeding Sepsis Pneumonia Sudden Death Overall ) Any death occurring within 1 month from treatment end, not related to disease progression Early ( 6 months) Merlano MC, Oral Oncol 2012 Late (> 6 months) Argiris A, Clin Cancer Res 2004
7 3 EFFICACY OF ICT (from MACC-HN 2000 analysis) Drug(s) makes the difference Table from E.E.Vokes 2010, modified
8 4 Surgical extension cannot be reduced on The basis of Chemotherapy response the extent of the primary tumor before CT was conducted by tattoo, photography Or both 32.5% of the frozen sections (initial tumor Extension) were involved with tumor and Necessitated further resection:
9 TAKE HOME MESSAGE The benefit of ICT depends on the drug(s) used The benefit of ICT may be improved by new drug combinations There is no evidence that ICT may reduce the extent of surgery. The same is for radiation volume. This choice might jeopardize results.
10 Locally advanced, unresectable HNC Vermorken TAX 323 Locally advanced, unresectable Locally advance, resectable but surgery refused Organ preservation Posner TAX 324
11 TAX 323 and 324: differences and cautions REGIMEN DOSES (mg/m 2 ) Antibiotic Profilax. G III/IV Neutrop. Febrile neutropenia Population Def. Treat. TAX 323 TPF PF T = 75 P = 75 F = 750 P = 100 F = 1000 yes 76.9% 5.2% no 52.5% 2.8% Unresectable RT TAX 324 TPF PF T = 75 P = 100 F = 1000 P = 100 F = 1000 yes 83%* 12%** no 56%* 7%** Resectable Unresctable Organ preservation Weekly Carbo + RT * = p < 0.001; ** = p = 0.04; for 5 days; for 4 days
12
13 TAKE HOME MESSAGE THE TRIPLET TAXANES CISPLATIN 5-FLUOROURACIL IS SUPERIOR TO P-F THE TRIPLET INCREASES THE RISK OF SEVERE EMATHOLOGICAL TOXICITY ANTIBIOTIC PROFILAXYS IS HIGHLY RECOMMENDED TAX 323 AND 324 HAVE BEEN DESIGNED TO COMPARE TWO REGIMENS OF ICT. THEY CANNOT ANSWER THE QUESTION WHETHER ICT MAY REPLACE CRT AS THE GOLDEN STANDARD FOR UNRESECTABLE LA-HNC
14 The today most interesting question Can the administration of induction chemotherapy prior to concomitant chemoradiotherapy further improve the results of either approach alone? 1 Third generation trials 1 ) Vokes EE, The Oncologist, 2010
15 TPF high dose and same pts population as in TAX 324
16
17
18
19
20
21 Arm A: TPF x 3 Arm B: PF x 3 Arm C: Standard CRT standard CRT standard CRT TPF low dose and same pts population as in TAX 323
22
23 Prior ICT impacts on the following CRT Regimen 3 CT courses < 3 CT courses TPF CRT 72.3% 27.7% PF CRT 75.0% 25.0% CRT 82.1% 17.9% Tremplin trial Regimen 3 CT courses < 3 CT courses TPF CRT 42% 58%
24 Cumulative conclusions, 3 TPF trials 1. All the trials failed to show any advantage by the addition of ICT to CRT 2. All the trials showed increase in toxicity compared to CRT alone 3. The worst toxic profile was observed with high dose TPF 4. ICT may negatively interfere with following standard CRT (as already observed in the Tremplin study) CRT REMAINS THE GOLD STANDARD AND THE REFERRAL REGIMEN FOR FUTURE RANDOMIZED TRIALS
25
26 ORGAN PRESERVATION EORTC RTOG 91-11
27 STUDIES DESIGN EORTC ARM A ARM B ALTERNATING CRT: CF x 4 + RADIOTHERAPY (60 Gy) PF x 2 RP PF x 2 RADIOTHERAPY (70 Gy) < RP SURGERY + RT ARM A PF x 3 RP RADIOTHERAPY (70 Gy) < RP SURGERY + RT RTOG ARM B CONCURRENT CRT: C x 3 + RADIOTHERAPY (70 Gy) ARM C RT (70 Gy)
28 EORTC RTOG 91-11
29 Overall survival (RTOG 91-11) HR = 1.25 C.I. = P = 0.08
30 Effects EORTC RTOG Alternating Sequential Sequential Concurrent CT / RT CT RT CT RT CT - RT Mucositis % G 2 35 P < G Late toxicities % 35 (fib.) 41 (fib.) P < ) Lefebvre J-L et al: J. Natl Cancer Inst 2009;101: ) Forastiere AA et al: N Engl J Med 2003;349:2091-8; updated ASCO ) Data at two years
31 Induction what? JNCI 2009 Docetaxel 75 Cisplatin 75 5 FU 750 vs Cisplatin FU 1000 RADIOTHERAPY 70 Gy
32 The main objective was the preservation of the larynx. Only the laryngectomy has been regarded as a failure, regardless whether the larynx was functioning or not Neither toxicity nor acute or late, nor survival or disease-free interval differ significantly between the two arms
33 1. ICT, Alternating CRT and Concurrent CRT are all acceptable approach to organ preservation. 2. ICT should be regarded as the best standard because of a better survival profile than concurrent CRT and a more easy delivery compared to alternating CRT. 3. There is evidence that TPF (European regimen) should be considered standard in organ preservation. CONCLUSIONS Locally Advanced HNC 1. Concurrent CRT offers a larger benefit than ICT followed by definitive locoregional treatment. 2. ICT followed by loco-regional treatment offers a larger benefit than locoregional treatment alone. 3. TPF is the referral regimen for ICT. The European scheduling should be preferred due to a better toxicity profile. 4. TPF is an aggressive regimen and deserves adequate supportive care. Organ preservation
Laryngeal and hypopharyngeal cancers
Laryngeal and hypopharyngeal cancers Induction Chemotherapy in combined modality approaches Atenas 16.09.2017 Ana Ferreira Castro, MD Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationSequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationOrgan-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari
Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation
More informationHead and NeckCancer: multi-modal therapeuticintegration
Head and NeckCancer: multi-modal therapeuticintegration P. Ponticelli, L. Lastrucci, R. De Majo, A. Rampini U.O.C. Radioterapia Ospedale S. Donato ASL 8 -AREZZO Summary Biological considerations Clinical
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationNeoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
More informationHead and Neck cancer
Head and Neck cancer Medical Oncologist s Role in Multidisciplinary Teams - Focus on Adjuvant & Neo-adjuvant Therapy - Hye Ryun Kim, M.D. Yonsei Cancer Center, Medical Oncology Contents I. Introduction
More information5/20/ ) Haffty GB: Concurrent chemoradiation in the treatment of head and neck cancer. Hematol. Oncol. Clin: North Am.
Prague, 24-25 25 April 29 ALTERNATING CHEMORADIATION: FOR WHOM? M. Merlano MD Holy Cross Gen. Hospital Cuneo - Italy ALTERNATING CHEMORADIATION: FOR WHOM? Definition of alternating chemoradiation Targets
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationNon-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit
Editorial Non-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit Hiroto Ishiki, Satoru Iwase Department of Palliative Medicine, The Institute of Medical
More informationLarynx Hypopharynx. Therapy algorithms. Why larynx preservation at all? State of the art Jean Louis Lefebvre,Lille Jan Klozar,Prague
Larynx Hypopharynx Moderation Rainald Knecht,Hamburg State of the art Jean Louis Lefebvre,Lille Debate pro CRT Jan Klozar,Prague contra CRT Marshall Posner,Boston Clinical cases all Therapy algorithms
More informationSanguineti s (2)Comment: When it was initially published in 2003 with a median follow-up of 3.8 years (4), the RTOG study led to a change in
Commento di due Soci AIRO pubblicati su due prestigiose riviste internazionali al Trial della forastiere et al. Long term results of RTOG:91-11 (a cura di Dr. Russi e Dr. Testolin )! Forastiere)et)al.)Long/Term)Results)of)RTOG)91/11:)A)Comparison)of)
More informationGuillaume Janoray, Yoann Pointreau, Pascal Garaud, Sophie Chapet, Marc Alfonsi, Christian Sire, Eric Jadaud, Gilles Calais
JNCI J Natl Cancer Inst (016) 108(4): djv368 doi:10.1093/jnci/djv368 First published online December 16, 015 Article Long-Term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy
More informationThe Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review
The Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review M.D. Al-Sarraf 1 1 Williams Beaumont Hospital, Royal Oak, Michigan, USA Introduction In the past, radiotherapy
More informationMultimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
Multimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) Amanda Psyrri, MD,FACP Attikon University Hospital Athens, Greece Learning objectives After reading and reviewing this material,
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationState of the Art: Management of Squamous Cell Carcinoma of the Head and Neck. Raul Giglio
State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck Raul Giglio Disclosures Nothing to disclose SCCHN Outline 1. General considerations: MTD 2. Epidemiology 3. Locoregional disease
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationRAMY R. GHALI, M.D.*; EMAN EL-SHARAWY, M.D.*; AZZA M. ADEL, M.D.* and SAMER A. IBRAHIM, M.D.**
Med. J. Cairo Univ., Vol. 79, No. 2, June: 13-18, 2011 www.medicaljournalofcairouniversity.com Induction Docetaxel, Cisplatin and 5 Fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy Versus Concomitant
More informationSAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital
SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction
More informationThe effect of induction chemotherapy followed by chemoradiotherapy in advanced head and neck cancer: a prospective study
International Journal of Research in Medical Sciences Nikam BM et al. Int J Res Med Sci. 2014 May;2(2):476-480 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: 10.5455/2320-6012.ijrms20140519
More informationAccepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179
ORIGINAL ARTICLE DOCETAXEL, CISPLATIN, AND FLUOROURACIL INDUCTION CHEMOTHERAPY FOLLOWED BY ACCELERATED FRACTIONATION/CONCOMITANT BOOST RADIATION AND CONCURRENT CISPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationPresent and Future of Head and Neck Cancer Therapy (Focus at systemic therapy)
Present and Future of Head and Neck Cancer Therapy (Focus at systemic therapy) Jan B; Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 1st Hellenic Conference
More informationThe Role of Docetaxel in the Treatment of Head and Neck Cancer
GBMC Head and Neck Conference The Role of Docetaxel in the Treatment of Head and Neck Cancer Simon Best December 7, 2007 Needs assessment: Providers who participate in the care of head and neck cancer
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationRADIATION THERAPY AND CHEMOTHERAPY IN LOCALLY ADVANCED CANCER OF THE HEAD AND NECK Carlos A. Perez, M.D. Former Chairman/Professor Emeritus
RADIATION THERAPY AND CHEMOTHERAPY IN LOCALLY ADVANCED CANCER OF THE HEAD AND NECK Carlos A. Perez, M.D. Former Chairman/Professor Emeritus Department of Radiation Oncology Mallinckrodt Institute of Radiology/
More informationHead and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More informationRecent Advances & Ongoing Challenges in Head & Neck Cancers
Recent Advances & Ongoing Challenges in Head & Neck Cancers Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard Medical School Boston, MA Disclosures
More informationNasopharyngeal Cancer:Role of Chemotherapy
Nasopharyngeal Cancer:Role of Chemotherapy PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 16/9/2017 2 nd Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationHead & Neck Cancer: When to Irradiate
Head & Neck Cancer: When to Irradiate ESO-ESMO Latin-America 2018 Talented students colleagues 1 > 15 different diseases for RT strategies NC NP OC OP H L 2 HPV Prognostic Marker >2010 Trial Cases Marker
More informationINAS I. ABDELHALIM, M.D.; NAWAL M. ELSAID, M.D.; ELSAID M. ALI, M.D. and BASHEER S. ATA, M.Sc.
Med. J. Cairo Univ., Vol. 81, No. 1, December: 887-893, 2013 www.medicaljournalofcairouniversity.net Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin and 5-Flurouracil Followed by Concomitent Chemoradiotherapy
More informationPractice teaching course on head and neck cancer management
28-29 October 2016 - Saint-Priest en Jarez, France Practice teaching course on head and neck cancer management IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Nicolas Magné France
More informationState of the art for radiotherapy of SCCHN
State of the art for radiotherapy of SCCHN Less side effects Cured More organ & function preservation Head & neck cancer = 42 000 new cases / year in Europe Not cured Local failure Distant failure More
More informationParadigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Paradigm Shift in the Treatment of Head and Neck Cancer: The
More informationTOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER
ORIGINAL ARTICLE TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER Dirk Rades, MD, 1 Fabian Fehlauer, MD, 2 Mashid Sheikh-Sarraf,
More informationOral Cavity Cancer Combined modality therapy
Oral Cavity Cancer Combined modality therapy Dr. Christos CHRISTOPOULOS Radiation Oncologist Head and Neck Cancers Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Disclosure slide I have no
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationTitle. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information
Title Clinical outcomes of weekly cisplatin chemoradiother Sakashita, Tomohiro; Homma, Akihiro; Hatakeyama, Hir Author(s) Takatsugu; Iizuka, Satoshi; Onimaru, Rikiya; Tsuchiy CitationInternational Journal
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationClinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationMoving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck
14 Journal of Cancer Research Updates, 2012, 1, 14-21 Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck Belisario A. Arango 1, Bertha
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationExpanding Role of the Medical Oncologist in the Management of Head and Neck Cancer Nicholas Choong and Everett Vokes DOI: /CA.2007.
Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer Nicholas Choong and Everett Vokes CA Cancer J Clin 2008;58;32-53; originally published online Dec 20, 2007; DOI: 10.3322/CA.2007.0004
More informationCetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
Cent. Eur. J. Med. 9(2) 2014 279-284 DOI: 10.2478/s11536-013-0154-9 Central European Journal of Medicine Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Jacopo Giuliani* 1, Marina
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More information17th ESO-ESMO Masterclass Clinical Oncology
Chemoradiotherapy and Systemic Therapy in Squamous Cell Carcinoma of the Head and Neck (SCCHN) Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 17 th
More informationASCO Highlights Head and Neck Cancer
ASCO Highlights Head and Neck Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head &
More informationROLE OF ALTERED FRACTIONATION & CHEMORADIATION IN HEAD AND NECK CANCER
ROLE OF ALTERED FRACTIONATION & CHEMORADIATION IN HEAD AND NECK CANCER What is conventional fractionation? Radiation is given at doses of 1.8 to 2.0 Gy delivered once daily, 5 days weekly for 6 to 7 weeks.
More informationThomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX
Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21
More informationRadio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology
Radio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology March 2018 > Half million new cases HNC/year in world 50-60% cured not cured
More informationHead&Neck, and Thyroid Cancers: Incorporating New Therapies into Current Treatment Algorithms
Head&Neck, and Thyroid Cancers: Incorporating New Therapies into Current Treatment Algorithms Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard
More informationTherapy of Locally Advanced Head and Neck Cancer: State of the Art
Therapy of Locally Advanced Head and Neck Cancer: State of the Art Barbara Burtness, MD Chief, Head and Neck ncology Medical ncology Co-Leader Senior Member Fox Chase Cancer Center Philadelphia, PA Therapy
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationLocally Advanced NSCLC and its management in the Elderly. Dr Laura Pemberton Consultant Clinical Oncologist, Christie Hospital, UK
Locally Advanced NSCLC and its management in the Elderly Dr Laura Pemberton Consultant Clinical Oncologist, Christie Hospital, UK Topics covered Concurrent Chemoradiotherapy (concrt) in elderly Radiotherapy
More informationComparative study of Gemcitabine versus Cisplatin concurrent with radiotherapy for locally advanced head and neck cancer
Journal of Cancer Treatment and Research 2014; 2(4): 37-44 Published online August 30, 2014 (http://www.sciencepublishinggroup.com/j/jctr) doi: 10.11648/j.jctr.20140204.12 Comparative study of Gemcitabine
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationConcurrent and sequential chemoradiotherapy. P. Van Houtte Department of Radiation Oncology Institut Jules Bordet
Concurrent and sequential chemoradiotherapy and radiotherapy for NSCLC P. Van Houtte Department of Radiation Oncology Institut Jules Bordet RADIOTHERAPY & CHEMOTHERAPY A very old concept «Benzene could
More informationUpdate on Head and Neck Cancer Outline. Presenter Disclosure Information. Head and Neck Cancer Primary Disease Sites. Epidemiology
Welcome to Master Class for Oncologists Miami, FL December 19, 2009 Session 5: 4:30 PM - 5:15 PM Head and Neck Cancer: Update on Comprehensive Management Speaker: David G. Pfister, MD Chief, Head & Neck
More informationHEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)
HEAD AND NECK CANCER TREATMENT S (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network (NCCN) recommends cancer patient participation in clinical trials as the gold standard for treatment.
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More informationState of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationKey words: Head-and-neck cancer, Chemoradiation, Concomitant Boost Radiation, Docetaxel. Materials and Methods
Weekly Cisplatin and Docetaxel plus Concomitant Boost Concurrently with Radiation Therapy in the Treatment of Locally Advanced Head And Neck Cancer: Phase II Trial Abd El Halim Abu-Hamar, MD 1, Naser Abd
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationDiagnosis and what happens after referral
Diagnosis and what happens after referral Dr Kate Newbold Consultant in Clinical Oncology The Royal Marsden Women's cancers Breast cancer introduction 1 Treatment Modalities Early stage disease -larynx
More informationMolecular targeting agents in the context of primary chemoradiation strategies
CLINICAL REVIEW Molecular targeting agents in the context of primary chemoradiation strategies Simon Laban, MD, 1 * Chia Jung Wang, MD, 1 Adrian Münscher, MD, 1 Silke Tribius, MD, 2 Philippe Schafhausen,
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationHEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)
HEAD AND NECK CANCER TREATMENT S (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network (NCCN) recommends cancer patient participation in clinical trials as the gold standard for treatment.
More informationClinical Discussion. Dr Pankaj Chaturvedi. Professor and Surgeon Tata Memorial Hospital
Clinical Discussion Dr Pankaj Chaturvedi Professor and Surgeon Tata Memorial Hospital chaturvedi.pankaj@gmail.com 47/M/smoker Hopkins : Transglottic lesion No cartilage infiltration but sclerosis Left
More informationComparing Alternative treatment Regimens for intermediate and high risk oropharyngeal cancer CompARE. Prof. Hisham Mehanna.
Comparing Alternative treatment Regimens for intermediate and high risk oropharyngeal cancer CompARE Prof. Hisham Mehanna Chief investigator: Hisham Mehanna Arm 1: Mehmet Sen Arm2: John Chester/Martin
More informationHypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen
ORIGINAL ARTICLE Hypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen Laurie Monnier, MD, 1 * Emmanuel Touboul, MD, PhD, 1 Catherine Durdux, MD, 2 Philippe Lang,
More informationBladder Preservation Strategies for Muscle Invasive Bladder Cancer
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationINTRODUCTION. Cancer Res Treat. 2007;39(3):93-98
Cancer Res Treat. 2007;39(3):93-98 The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer Jae-Sook
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
More information